Table 1.
Patients’ characteristics.
| Variables | Patients (N. 62) |
|---|---|
| Age at vaccination (years), median (range) | 71.9 (33.7–86.3) |
| Male, n (%) | 35 (56.5) |
| BMI (kg/m2), median (range) | 24.5 (19.1–37.4) |
| Diagnosis, n (%) | |
| PV | 21 (33.9) |
| ET | 11 (17.7) |
| Myelofibrosis | 26 (41.9) |
| PMF | 15 (24.2) |
| SMF | 11 (17.7) |
| MPN, U | 4 (6.5) |
| Driver mutations, n (%) | |
| JAK2V617F | 49 (79.1) |
| CALR | 10 (16.1) |
| MPL | 2 (3.2) |
| Triple negative | 1 (1.6) |
| Cytoreductive therapy at vaccination, n (%) | |
| Hydroxyurea | 15 (24.2) |
| Anagrelide | 3 (4.8) |
| Interferon | 4 (6.5) |
| Givinostat | 3 (4.8) |
| Ruxolitinib | 30 (48.4) |
| Other JAK inhibitors | 2 (3.2) |
| No therapy | 5 (8.1) |
| Ruxolitinib daily dose (mg), median (range) | 20 (10–40) |
| Vaccine type, n (%) | |
| BNT162b2 (Pfizer-BioNTech) | 22 (35.5) |
| mRNA-1273 (Moderna) | 40 (64.5) |
| Time from MPN diagnosis to vaccination (years), median (range) | 9.7 (0.1–36.2) |
| Time from ongoing treatment start to vaccination (years), median (range) | 3.1 (0.1–18.5) |
BMI body mass index, PV polycythemia vera, ET essential thrombocythemia, PMF primary myelofibrosis, SMF secondary myelofibrosis, MPN, U myeloproliferative neoplasm, unclassifiable.